A novel <i>ex vivo</i> high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.

Oncotarget · 2018 · PMC5995261 · PMID 29899839

Europe PMC DOI

hedged sentence

0.5000

closest p · 10.0× alpha

0.5000

boldest claim

The sentences

showed a trendp = 0.5not close (p > 0.1)

We found that U-CLL cases showed a significantly more prominent proliferative response (48 ± 27% vs 17 ± 14% for M-CLL; p < 0.001); however, no significant differences were evident in terms of apoptosis, although U-CLL cases showed a trend for more homogeneous protection (25 ± 19 vs 38 ± 19 in U-CLL vs M-CLL cases; p = 0.5).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.